Search - tctmd.com

Displaying 361 - 380 of 914

Sort: Relevancy | Date

Studies Reveal Surprising Benefits of Smoking Cessation and ‘Greenness’

News Conference News ESC 2021

Studies Reveal Surprising Benefits of Smoking Cessation and ‘Greenness’

August 28, 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

News Conference News ESC 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

August 24, 2021

J-Curve for Alcohol and AF Risk? UK Biobank Offers ‘Glimmer of Hope’

News Conference News HRS 2021

J-Curve for Alcohol and AF Risk? UK Biobank Offers ‘Glimmer of Hope’

July 28, 2021

COVID-19’s Effects on Cardiac Imaging Protocols, Perspectives Still Unfolding

News Conference News SCCT 2021

COVID-19’s Effects on Cardiac Imaging Protocols, Perspectives Still Unfolding

Yael L. Maxwell

July 23, 2021

Timing of Mitral Surgery After Failed TEER Influences Outcomes

News Conference News TVT 2021

Timing of Mitral Surgery After Failed TEER Influences Outcomes

July 21, 2021

As New Guidelines Loom, CT Community Seeks to Fill Knowledge Gaps

News Conference News SCCT 2021

As New Guidelines Loom, CT Community Seeks to Fill Knowledge Gaps

Yael L. Maxwell

July 20, 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Transradial PCI Bests Femoral Access in Complex Cases: COLOR

News Conference News EuroPCR 2021

Transradial PCI Bests Femoral Access in Complex Cases: COLOR

Michael O'Riordan

May 21, 2021

Tricuspid Trio: TRISCEND, CLASP TR, and TriBAND Studies Show Advances

News Conference News EuroPCR 2021

Tricuspid Trio: TRISCEND, CLASP TR, and TriBAND Studies Show Advances

May 21, 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

News Conference News EuroPCR 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

Michael O'Riordan

May 18, 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

Lancet Commission on CVD in Women Aims to Slash Global Burden

News Conference News ACC 2021

Lancet Commission on CVD in Women Aims to Slash Global Burden

May 17, 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

May 16, 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

News Conference News ACC 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

May 16, 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

News Conference News ACC 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Yael L. Maxwell

May 15, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.